CRP and COVID-19: Methylprednisolone has a higher lung tissue concentration-to-plasma and faster onset of action in comparison to dexamethasone which could make it more potent in lung injury [24]. Moreover, plasma inflammatory markers in COVID-19 patients, such as CRP and interleukin-6 (IL-6), have been shown to be significantly lower after methylprednisolone use.